📊 RYTM Key Takeaways
Is Rhythm Pharmaceuticals, Inc.. (RYTM) a Good Investment?
Rhythm Pharmaceuticals shows impressive 45.8% revenue growth, but operates at massive scale losses (-$192M operating loss on $189.8M revenue) with only ~5.6 months of cash runway at current -$115.7M annual operating burn. While loss improvement trends are positive, near-term capital requirements and high execution risk outweigh growth momentum.
Why Buy Rhythm Pharmaceuticals, Inc.. Stock? RYTM Key Strengths
- Strong revenue growth of 45.8% YoY demonstrates significant market demand and commercialization progress
- Improving loss trajectory with YoY loss reduction of 2.7%, suggesting operational leverage potential
- Excellent liquidity position with 4.41x current ratio and 4.16x quick ratio providing near-term operational flexibility
- Moderate leverage at 0.73x debt/equity maintains balance sheet flexibility for refinancing or capital raises
RYTM Stock Risks: Rhythm Pharmaceuticals, Inc.. Investment Risks
- Severe cash burn of -$115.7M annually with only $54.3M cash reserves creates critical ~5.6 month runway requiring immediate capital raise
- Operating margin of -101.2% indicates company is losing more than $1 for every $1 of revenue, making current unit economics unsustainable
- Path to profitability unclear; company must achieve 2x+ revenue growth or 50%+ cost reduction to breakeven at current scale
- Biotech sector execution risk: profitability depends on sustained product demand, regulatory environment, and competitive landscape
Key Metrics to Watch
- Monthly operating cash burn trend and cash position depletion rate
- Gross margin expansion and revenue per dollar of operating expense efficiency
- Time to profitability projection based on current growth trajectory and cost structure
- Capital raise announcements, terms, and shareholder dilution impact
Rhythm Pharmaceuticals, Inc.. (RYTM) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 4.41x current ratio provides a solid financial cushion.
RYTM Profit Margin, ROE & Profitability Analysis
RYTM vs Healthcare Sector: How Rhythm Pharmaceuticals, Inc.. Compares
How Rhythm Pharmaceuticals, Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Rhythm Pharmaceuticals, Inc.. Stock Overvalued? RYTM Valuation Analysis 2026
Based on fundamental analysis, Rhythm Pharmaceuticals, Inc.. shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Rhythm Pharmaceuticals, Inc.. Balance Sheet: RYTM Debt, Cash & Liquidity
RYTM Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Rhythm Pharmaceuticals, Inc..'s revenue has grown significantly by 145% over the 5-year period, indicating strong business expansion. The most recent EPS of $-3.20 indicates the company is currently unprofitable.
RYTM Revenue Growth, EPS Growth & YoY Performance
RYTM Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $33.3M | -$32.3M | $-0.73 |
| Q2 2025 | $29.1M | -$32.3M | $-0.55 |
| Q1 2025 | $26.0M | -$49.5M | $-0.81 |
| Q3 2024 | $22.5M | -$32.3M | $-0.73 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Rhythm Pharmaceuticals, Inc.. Dividends, Buybacks & Capital Allocation
RYTM SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Rhythm Pharmaceuticals, Inc.. (CIK: 0001649904)
📋 Recent SEC Filings
❓ Frequently Asked Questions about RYTM
What is the AI rating for RYTM?
Rhythm Pharmaceuticals, Inc.. (RYTM) has an AI rating of SELL with 78% confidence, based on fundamental analysis of SEC EDGAR filings.
What are RYTM's key strengths?
Claude: Strong revenue growth of 45.8% YoY demonstrates significant market demand and commercialization progress. Improving loss trajectory with YoY loss reduction of 2.7%, suggesting operational leverage potential.
What are the risks of investing in RYTM?
Claude: Severe cash burn of -$115.7M annually with only $54.3M cash reserves creates critical ~5.6 month runway requiring immediate capital raise. Operating margin of -101.2% indicates company is losing more than $1 for every $1 of revenue, making current unit economics unsustainable.
What is RYTM's revenue and growth?
Rhythm Pharmaceuticals, Inc.. reported revenue of $189.8M.
Does RYTM pay dividends?
Rhythm Pharmaceuticals, Inc.. does not currently pay dividends.
Where can I find RYTM SEC filings?
Official SEC filings for Rhythm Pharmaceuticals, Inc.. (CIK: 0001649904) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is RYTM's EPS?
Rhythm Pharmaceuticals, Inc.. has a diluted EPS of $-3.11.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is RYTM a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Rhythm Pharmaceuticals, Inc.. has a SELL rating with 78% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is RYTM stock overvalued or undervalued?
Valuation metrics for RYTM: ROE of -141.3% (sector avg: 15%), net margin of -103.6% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy RYTM stock in 2026?
Our dual AI analysis gives Rhythm Pharmaceuticals, Inc.. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is RYTM's free cash flow?
Rhythm Pharmaceuticals, Inc..'s operating cash flow is $-115.7M, with capital expenditures of $953.0K. FCF margin is -61.5%.
How does RYTM compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -103.6% (avg: 12%), ROE -141.3% (avg: 15%), current ratio 4.41 (avg: 2).